News

Thermo Fisher Scientific to add 500 jobs in RVA region

Scientific equipment supplier will invest $97M in three new labs

(Virginia Business) Massachusetts-based scientific equipment and software supply company Thermo Fisher Scientific Inc. will invest $97 million to expand its laboratory operations into three new locations in the Greater Richmond area, a project expected to create more than 500 jobs, Gov. Glenn Youngkin announced Monday.

“Thermo Fisher’s expanding footprint and creation of more than 500 new jobs is a major win for the Greater Richmond region and Virginia’s life sciences industry,” Youngkin said in a statement. “This sector has gained significant momentum in the commonwealth due to our research institutions, skilled talent and advanced innovation ecosystem, and we are proud of the company’s developments happening right here in Virginia.”

Thermo Fisher will be adding nearly 150,000 square feet to its Richmond-area operations. It acquired the labs through its purchase of PPD Inc. in December 2021.

The company will establish two new bioanalytical labs in Henrico County at 2250 Dabney Road and 8700 Quioccasin Road, the former Toys “R” Us store that it is renovating. The third lab will be at the VA Bio+Tech Park in downtown Richmond near VCU Medical Center.

“We have a rich history in the Richmond and Henrico County region, a talent hub with respected universities and an attractive place for our employees to live and work,” said David M. Johnston, senior vice president and president of clinical research for Thermo Fisher Scientific, in a statement. “We value our strong collaborative relationship with the commonwealth of Virginia, Henrico County and the city of Richmond. These vital relationships are an important reason our laboratories employ more than 1,400 professionals and that we have expanded our bioanalytical, biomarker and vaccine sciences operations to include more than 300,000 square feet of scientific work space.”

The Virginia Economic Development Partnership worked with the Henrico Economic Development Authority, the city of Richmond and the VA Bio+Tech Park to secure the projects. Former Gov. Ralph Northam approved a $1 million grant from the Virginia Investment Performance program, an incentive that encourages existing Virginia companies to invest capital. Northam also approved $2 million from the Commonwealth’s Opportunity Fund to assist Henrico County, and $151,952 for the city of Richmond project. Thermo Fisher is eligible to receive state benefits from the Virginia Enterprise Zone Program, administered by the Virginia Department of Housing and Community Development, and the Major Business Facility Job Tax Credit for full-time jobs created.

The Virginia Talent Accelerator Program, a workforce initiative created by the VEDP and Virginia Community College System, would provide customizable recruitment and training services at no cost to the company.

Read more here.

Recent News

03/19/2026

GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced a new genetic testing program with Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a commercial-stage biopharmaceutical company focused on bringing life-changing therapeutics to people living with rare diseases. The Niemann-Pick Disease type C (NPC) Sponsored Genetic Testing

03/18/2026

Phlow Corp. Appoints Dawn Von Rohr as Chief Operating Officer to Advance Domestic Pharmaceutical Manufacturing

Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that Dawn Von Rohr has been appointed Chief Operating Officer (COO). Von Rohr will oversee Phlow’s operations, manufacturing execution, and strategic growth initiatives as the company continues expanding its advanced pharmaceutical development and manufacturing infrastructure in the United States to

03/17/2026

W&M Undergrads expand the chemical toolbox for cancer drugs

Thanks to modern therapies, a cancer diagnosis is no longer an automatic death sentence. But many patients still suffer from unwanted side effects and limited efficacy. In a recent Bioconjugate Chemistry publication, William & Mary researchers designed an antibody-drug conjugate (ADC) with the potential to improve the potency and decrease the cost of currently approved cancer drugs. Like